Characterization of recombinant human protein C inhibitor expressed in Escherichia coli

被引:21
作者
Réhault, SM
Zechmeister-Machhart, M
Fortenberry, YM
Malleier, J
Binz, NM
Cooper, ST
Geiger, M
Church, FC
机构
[1] Univ N Carolina, Sch Med, Div Hematol Oncol Med, Dept Pathol & Lab Med,Cardiovasc Biol Ctr, Chapel Hill, NC 27599 USA
[2] Univ N Carolina, Sch Med, Dept Pharmacol, Cardiovasc Biol Ctr, Chapel Hill, NC 27599 USA
[3] Univ N Carolina, Sch Med, Dept Med, Cardiovasc Biol Ctr, Chapel Hill, NC 27599 USA
[4] Med Univ Vienna, Dept Vasc Biol & Thrombosis Res, A-1090 Vienna, Austria
来源
BIOCHIMICA ET BIOPHYSICA ACTA-PROTEINS AND PROTEOMICS | 2005年 / 1748卷 / 01期
关键词
serpin; recombinant protein C inhibitor; thrombin; heparin; purification;
D O I
10.1016/j.bbapap.2004.12.003
中图分类号
Q5 [生物化学]; Q7 [分子生物学];
学科分类号
071010 ; 081704 ;
摘要
The serine protease inhibitor (serpin) protein C inhibitor (PCI; also named plasminogen activator inhibitor-3) regulates serme proteases in hemostasis, fibrinolysis, and reproduction. The biochemical activity of PCI is not fully defined partly due to the lack of a convenient expression system for active rPCI. Using pET-15b plasmid, Ni2+-chelate and heparin-Sepharose affinity chromatography steps, we describe here the expression, purification and characterization of wild-type recombinant (wt-rPCI) and two inactive mutants, R354A (P1 residue) and T341R (P14 residue), expressed in Escherichia coli. Wild-type rPCI, but not the two mutants, formed a stable bimolecular complex with thrombin, activated protein C and urokinase. In the absence of heparin, wt-rPCI-thrombin, -activated protein C, and -urokinase inhibition rates were 56.7, 3.4, and 2.3 X 10(4) M-1 min(-1), respectively, and the inhibition rates were accelerated 25-, 71-, and 265-fold in the presence of 10 mu g/mL heparin for each respective inhibition reaction. The stoichiometry of inhibition (SI) for wt-rPCI-thrombin was 2.0, which is comparable to plasma-derived PCL The present report describes for the first time the expression and characterization of recombinant PCI in a bacterial expression system and demonstrates the feasibility of using this system to obtain adequate amounts of biologically active rPCI for future structure-function studies. (c) 2004 Elsevier B.V All rights reserved.
引用
收藏
页码:57 / 65
页数:9
相关论文
共 65 条
[1]  
BAJOU K, 2004, ONCOGENE
[2]   Expression of protein C inhibitor (PCI) in benign and malignant prostatic tissues [J].
Cao, Y ;
Becker, C ;
Lundwall, Å ;
Christensson, A ;
Gadaleanu, V ;
Lilja, H ;
Bjartell, A .
PROSTATE, 2003, 57 (03) :196-204
[3]  
CHAI KX, 1993, J BIOL CHEM, V268, P24498
[4]   INTERMOLECULAR INTERACTIONS BETWEEN PROTEIN-C INHIBITOR AND COAGULATION PROTEASES [J].
COOPER, ST ;
WHINNA, HC ;
JACKSON, TP ;
BOYD, JM ;
CHURCH, FC .
BIOCHEMISTRY, 1995, 34 (40) :12991-12997
[5]   Isolation of prostatic kallikrein hK2, also known as hGK-1, in human seminal plasma [J].
Deperthes, D ;
Chapdelaine, P ;
Tremblay, RR ;
Brunet, C ;
Berton, J ;
Hebert, J ;
Lazure, C ;
Dube, JY .
BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS, 1995, 1245 (03) :311-316
[6]  
DERECHIN VM, 1990, J BIOL CHEM, V265, P5623
[7]   Heparin binding of protein-C inhibitor - Analysis of the effect of heparin on the interaction of protein-C inhibitor with tissue kallikrein [J].
Ecke, S ;
Geiger, M ;
Binder, BR .
EUROPEAN JOURNAL OF BIOCHEMISTRY, 1997, 248 (02) :475-480
[8]   Protein C inhibitor acts as a procoagulant by inhibiting the thrombomodulin-induced activation of protein C in human plasma [J].
Elisen, MGLM ;
von dem Borne, PAK ;
Bouma, BN ;
Meijers, JCM .
BLOOD, 1998, 91 (05) :1542-1547
[9]   Inhibition of serine proteases by reactive site mutants of protein C inhibitor (plasminogen activator inhibitor-3) [J].
Elisen, MGLM ;
Bouma, BN ;
Church, FC ;
Meijers, JCM .
FIBRINOLYSIS & PROTEOLYSIS, 1998, 12 (05) :283-291
[10]   Protein C inhibitor may modulate human sperm-oocyte interactions [J].
Elisen, MGLM ;
van Kooij, RJ ;
Nolte, MA ;
Marquart, JA ;
Lock, TMTWT ;
Bouma, BN ;
Meijers, JCM .
BIOLOGY OF REPRODUCTION, 1998, 58 (03) :670-677